Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Euroz Hartleys Healthcare Forum 2023
21 slides from Proteomics International Laboratories's conference presentation, Feb 2, 2023
Slide 1: ASX release: Investor Presentation
ASX release 2 February 2023 ASX code: PIQ For personal use only Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at Euroz Hartleys Healthcare Forum
Slide 2: Investor Presentation - Euroz Hartleys Healthcare Forum
ASX: PIQ For personal use only Proteomics International LABORATORIES LTD Investor Presentation Euroz Hartleys Healthcare Forum 2 February 2023 Dr. Richard Lipscombe Managing Director 1
Slide 3: Disclaimer
Disclaimer ASX: PIQ For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors o
Slide 4: Corporate Snapshot
Proteomics International Laboratories Ltd ASX: PIQ Corporate Snapshot – 30/01/2023 A medical technology company at the forefront of For personal use only ASX code PIQ precision medicine and predictive diagnostics Share Price A$1.125 Diagnostics (Dx) Shares on issue (+5.7m options) 118m PromarkerD Ma
Slide 5: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ For personal use only PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagn
Slide 6: For personal use only
For personal use only ASX: PIQ 5
Slide 7: Problem and Solution
Problem and Solution ASX: PIQ For personal use only Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the onset Roadblock of diabetic kidney disease The Probl
Slide 8: PromarkerD is Revenue Ready
PromarkerD is Revenue Ready ASX: PIQ Key highlights towards a global roll-out For personal use only Enormous Market ✓ 537m adults have diabetes globally: 1-in-3 currently have diabetic kidney disease (DKD) Peer reviewed publications – Clinical & analytical validity proven (Sensitivity 86%); High Sta
Slide 9: PromarkerD – Simple Integration & Utilisation
PromarkerD – Simple Integration & Utilisation ASX: PIQ For personal use only Blood sample drawn Biomarkers analysed Results analysed by Results and intervention plan PromarkerD Hub software delivered Sample is drawn at clinic or Laboratory uses a standard Cloud based algorithm, the Clinician deliver
Slide 10: PromarkerD Market Opportunity
PromarkerD Market Opportunity ASX: PIQ Diabetes incidence and Patent portfolio 45% For personal use only undiagnosed Country Patent/Application No Patent Status No. Diabetics1 Australia 2011305050 Granted 1,491,800 Brazil BR112013006740 Granted 15,733,600 Canada 2811654 Granted 2,974,000 China ZL201
Slide 11: PromarkerD – Route to US and Global Markets
PromarkerD – Route to US and Global Markets ASX: PIQ Diagnostic laboratory Key Markets For personal use only licenses PromarkerDTM United States • Binding Letter of Intent signed with Sonic Healthcare USA • LOI details terms and conditions to market and sell PromarkerD in the USA Immunoassay kits ma
Slide 12: Diagnostics Pipeline
Diagnostics Pipeline ASX: PIQ For personal use only The Promarker™ Research Further Global Potential in New Markets Pipeline & Timeline • Employs the Promarker™ technology platform to develop novel intellectual property • Targeting new diagnostic tests in areas of significant unmet need • Enormous m
Slide 13: In Development: Endometriosis and Oesophageal Cancer
In Development: Endometriosis • Endometriosis is a common and painful disease where tissue that normally lines the uterus grows into other organs For personal use only • Currently diagnosis takes an average of 7.5 years and requires invasive surgery (laparoscopy) • Affects 1 in 9 women and costs Aus
Slide 14: Timeline & Milestones
Timeline & Milestones ASX: PIQ 2022 Achievements 2023 Targets & Milestones For personal use only 07 ? s e 0. 00 / 2 Bca 0. 00 / ? s e 0. 00 OxiDx P/L spin- UK NICE Potential breakthrough out launched for publishes Finalisation of / 4 Hsl 0. 00 blood test able to detect oxidative stress Medtech Sonic
Slide 15: Value Inflection Points
Value Inflection Points ASX: PIQ For personal use only Share Price Catalysts throughout CY23 Exceptional Global Opportunity 1H 2H Milestone CY23 CY23 Impact Disruptive, cutting-edge technology & proven in-house diagnostics platform PromarkerD Execution of Sonic Healthcare USA licence; PromarkerD
Slide 16: Peer Comparison
Peer Comparison ASX: PIQ Stock Market Share FY22 FY22 Net For personal use only Company Focus Code Capitalisation Price Revenue Profit/Loss Proteomics Predictive blood test measuring novel protein biomarkers for DKD; simple, cost effective, commercial ready. International PIQ.ASX Pipeline of novel d
Slide 17: Contact
Contact ASX: PIQ For personal use only Dr Richard Lipscombe Kyle Moss Managing Director Corporate Advisor T: +61 8 9389 1992 Euroz Hartleys E: enquiries@proteomicsinternational.com T: +61 9488 1400 www.proteomicsinternational.com E: kmoss@eurozhartleys.com Dirk van Dissel Investor Relations & Corpor
Slide 18: Supplemental
Supplemental ASX: PIQ For personal use only 17
Slide 19: Board of Directors
Board of Directors ASX: PIQ Neville Gardiner BBus (Accounting and Business Law) (Curtin), Non-Executive Chair For personal use only Seasoned finance professional with over 30 years’ experience providing corporate advice to Boards of public and private companies. South & He was Co-Founder and MD of T
Slide 20: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention ASX: PIQ For personal use only How PromarkerD results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabet
Slide 21: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ PromarkerD significantly enhances diabetic kidney disease diagnosis and management For personal use only Peer reviewed PromarkerD tested on over 5,000 patients in 4-year clinical studies PromarkerD predicted 86% of otherwise healthy patients with T2D who went on to
Proteomics International Laboratories — Euroz Hartleys Healthcare Forum 2023 on 6ix